Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) went up by 2.66% from its latest closing price compared to the recent 1-year high of $9.78. The company’s stock price has collected -79.14% of loss in the last five trading sessions. Press Release reported on 09/08/20 that Corbus Pharmaceuticals Announces Topline Results from RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
Is It Worth Investing in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ :CRBP) Right Now?
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) scored a price-to-earnings ratio above its average ratio, recording 19.71 x from its present earnings ratio. Plus, the 36-month beta value for CRBP is at 1.85. Opinions of the stock are interesting as 1 analysts out of 6 who provided ratings for Corbus Pharmaceuticals Holdings, Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 5 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $3.63, which is -$1.93 below the current price. CRBP currently public float of 73.07M and currently shorts hold a 21.40% ratio of that float. Today, the average trading volume of CRBP was 3.02M shares.
CRBP’s Market Performance
CRBP stocks went down by -79.14% for the week, with a monthly drop of -73.69% and a quarterly performance of -72.99%, while its annual performance rate touched -66.38%. The volatility ratio for the week stands at 17.58% while the volatility levels for the past 30 days are set at 9.91% for Corbus Pharmaceuticals Holdings, Inc.. The simple moving average for the period of the last 20 days is -72.96% for CRBP stocks with a simple moving average of -69.34% for the last 200 days.
Analysts’ Opinion of CRBP
Many brokerage firms have already submitted their reports for CRBP stocks, with ROTH Capital repeating the rating for CRBP by listing it as a “Neutral.” The predicted price for CRBP in the upcoming period, according to ROTH Capital is $3 based on the research report published on September 8th of the current year 2020.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see CRBP reach a price target of $3. The rating they have provided for CRBP stocks is “Sector Perform” according to the report published on September 8th, 2020.
Jefferies gave a rating of “ Hold” to CRBP, setting the target price at $2.50 in the report published on September 8th of the current year.
CRBP Trading at -72.80% from the 50-Day Moving Average
After a stumble in the market that brought CRBP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -80.27% of loss for the given period.
Volatility was left at 9.91%, however, over the last 30 days, the volatility rate increased by 17.58%, as shares sank -72.31% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -75.72% lower at present.
During the last 5 trading sessions, CRBP fell by -79.14%, which changed the moving average for the period of 200-days by -57.77% in comparison to the 20-day moving average, which settled at $6.8847. In addition, Corbus Pharmaceuticals Holdings, Inc. saw -64.65% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at CRBP starting from Millian Craig Stuart, who bought 2,000 shares at the price of $4.25 back on Mar 17. After this action, Millian Craig Stuart now owns 12,000 shares of Corbus Pharmaceuticals Holdings, Inc., valued at $8,500 using the latest closing price.
Cohen Yuval, the Chief Executive Officer of Corbus Pharmaceuticals Holdings, Inc., bought 4,300 shares at $3.49 during a trade that took place back on Mar 17, which means that Cohen Yuval is holding 71,090 shares at $15,007 based on the most recent closing price.
Stock Fundamentals for CRBP
Current profitability levels for the company are sitting at:
- -226.01 for the present operating margin
The net margin for Corbus Pharmaceuticals Holdings, Inc. stands at -197.69. The total capital return value is set at -375.38, while invested capital returns managed to touch -342.06. Equity return is now at value -430.80, with -164.10 for asset returns.
Based on Corbus Pharmaceuticals Holdings, Inc. (CRBP), the company’s capital structure generated 153.40 points at debt to equity in total, while total debt to capital is 60.54. Total debt to assets is 19.22, with long-term debt to equity ratio resting at -4,293.64. Finally, the long-term debt to capital ratio is 131.50.
When we switch over and look at the enterprise to sales, we see a ratio of 9.04, with the company’s debt to enterprise value settled at 0.03. The receivables turnover for the company is 26.96 and the total asset turnover is 0.75. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.09.